Ben Fidler
Senior Editor | @BentheFidlerBen is a senior editor for BioPharma Dive. He is a veteran business journalist with 15 years of experience covering a variety of sectors. Prior to joining Industry Dive, Ben spent six-plus years with Xconomy writing about biotech, specializing in unique angles, profiles, features, enterprise pieces and more. A lifelong New Yorker, Brooklyn transplant and Yankees/Giants/Knicks fan, Ben is trying to cope with a recent move to the suburbs of Virginia, where he spends most of his time chasing after his rambunctious toddler. Ben has a B.A. from Binghamton University.
441 articles by Ben Fidler
-
5 FDA decisions to watch in the fourth quarter
Oct. 3, 2022 -
Solid Bio yields to Sarepta on Duchenne with plans for merger, R&D shakeup
Sept. 30, 2022 -
Prime Medicine becomes the next high-profile biotech to test IPO waters
Sept. 26, 2022 -
Servier cuts ties with Allogene, ending complex CAR-T partnership
Sept. 22, 2022 -
GSK buys into Spero’s comeback plan
Sept. 22, 2022 -
Rocket gives struggling gene therapy company a lifeline after SPAC merger
Sept. 20, 2022 -
Intellia offers first look at CRISPR drug for rare swelling disorder
Sept. 16, 2022 -
Third Harmonic boosts biotech with sector’s top IPO in four months
Sept. 15, 2022 -
Akero shares soar as NASH drug succeeds in mid-stage trial
Sept. 13, 2022 -
Can biotech IPOs bounce back? Third Harmonic to test investor appetite with planned offering
Sept. 13, 2022 -
Regeneron answers rivals with data for new version of top-selling eye drug
Sept. 8, 2022 -
Alnylam details anticipated results from heart disease drug trial
Sept. 8, 2022 -
Iveric readies eye drug for FDA following study success
Sept. 6, 2022 -
Novartis’ Bradner steps down as research head amid company shake-up
Sept. 1, 2022 -
Takeda ends deal with Finch as bumpy ride continues for microbiome drugs
Aug. 26, 2022 -
Ovid turns to gene therapy startup to restock drug pipeline
Aug. 24, 2022 -
Aerie’s glaucoma drug journey ends in $770M sale to Alcon
Aug. 23, 2022 -
Axsome rebounds to win FDA approval of depression drug
Aug. 19, 2022 -
Schrödinger names longtime biotech analyst Porges its CFO and top dealmaker
Aug. 18, 2022 -
Blueprint drug succeeds in rare disease study important to its market prospects
Aug. 17, 2022 -
Merck pays startup Orna $150M as ‘circular RNA’ attracts industry interest
Aug. 16, 2022 -
‘Treg’ cell therapy: bringing CAR-T to autoimmune disease
Aug. 16, 2022 -
Seagen loses arbitration case to Daiichi Sankyo over cancer drug technology
Aug. 12, 2022 -
New Enhertu approval adds to growing role of well-known cancer target
Aug. 12, 2022 -
GentiBio partners with Bristol Myers as cell therapy for immune disease gains momentum
Aug. 10, 2022